drugset / Trial / NCT02736812

Summary

In severe bleeding due to trauma, a decrease in coagulation factors maintains and promotes bleeding. The plasma allows, through its contribution of coagulation factors, early prevention or correction of this post-trauma induced coagulopathy. This study aims to measure the effectiveness of pre-hospital FLYP administration in case of traumatic hemorrhagic shock, in the occurrence or the treatment of a post traumatic induced coagulopathy. Study Design This is a randomized controlled multicenter open label study in two parallel groups. Eligibility criteria : adult, victim of a hemorrhagic shock of traumatic origin with \[systolic blood pressure \<70 mmHg\] or Shock Index \>1.1 The patients will receive either FLYP either the usual treatment as given in the recommendations for best practice. The primary endpoint is the International Normalized Ratio (INR) at hospital admission. The study must confirm the link between causality of early administration of plasma in improving post-traumatic coagulopathy. The study must show safe usage in out-of-hospital situations and the ability of medical staff to meet the requirements of the health authorities in terms of product use as well as in terms of traceability of the victims and the treatment they received.

Timeline

Start
2016-04-01
Primary completion
2019-10-31
Completion
2019-11-30

Outcome

Missed primary endpoint

paper prehospital transfusion of lyophilized plasma was not associated with significant differences in INR values vs standard care with normal saline infusion. PMID 35881397 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject French Lyophilized Plasma Other / unclassified — —

Indications

No indication recorded.